nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—RAF1—dilated cardiomyopathy	0.867	1	CbGaD
Vemurafenib—Vasculitis—Spironolactone—dilated cardiomyopathy	0.00239	0.0467	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00152	0.0298	CcSEcCtD
Vemurafenib—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00145	0.0283	CcSEcCtD
Vemurafenib—Vasculitis—Furosemide—dilated cardiomyopathy	0.0013	0.0254	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00129	0.0253	CcSEcCtD
Vemurafenib—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00111	0.0217	CcSEcCtD
Vemurafenib—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00105	0.0205	CcSEcCtD
Vemurafenib—Alopecia—Spironolactone—dilated cardiomyopathy	0.00104	0.0202	CcSEcCtD
Vemurafenib—Vasculitis—Lisinopril—dilated cardiomyopathy	0.000976	0.0191	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.000964	0.0188	CcSEcCtD
Vemurafenib—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000832	0.0163	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000829	0.0162	CcSEcCtD
Vemurafenib—Eosinophilia—Furosemide—dilated cardiomyopathy	0.000788	0.0154	CcSEcCtD
Vemurafenib—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.000787	0.0154	CcSEcCtD
Vemurafenib—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000729	0.0143	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000727	0.0142	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000718	0.0141	CcSEcCtD
Vemurafenib—Arthritis—Lisinopril—dilated cardiomyopathy	0.000711	0.0139	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000704	0.0138	CcSEcCtD
Vemurafenib—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000691	0.0135	CcSEcCtD
Vemurafenib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000658	0.0129	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000622	0.0122	CcSEcCtD
Vemurafenib—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000613	0.012	CcSEcCtD
Vemurafenib—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000603	0.0118	CcSEcCtD
Vemurafenib—Eye disorder—Furosemide—dilated cardiomyopathy	0.000596	0.0116	CcSEcCtD
Vemurafenib—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000591	0.0116	CcSEcCtD
Vemurafenib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000589	0.0115	CcSEcCtD
Vemurafenib—Angiopathy—Furosemide—dilated cardiomyopathy	0.000578	0.0113	CcSEcCtD
Vemurafenib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000569	0.0111	CcSEcCtD
Vemurafenib—Erythema—Furosemide—dilated cardiomyopathy	0.000555	0.0108	CcSEcCtD
Vemurafenib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000555	0.0108	CcSEcCtD
Vemurafenib—Dizziness—Spironolactone—dilated cardiomyopathy	0.00055	0.0108	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000545	0.0107	CcSEcCtD
Vemurafenib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000543	0.0106	CcSEcCtD
Vemurafenib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00054	0.0106	CcSEcCtD
Vemurafenib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000529	0.0103	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000528	0.0103	CcSEcCtD
Vemurafenib—Rash—Spironolactone—dilated cardiomyopathy	0.000525	0.0103	CcSEcCtD
Vemurafenib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000524	0.0103	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000522	0.0102	CcSEcCtD
Vemurafenib—Headache—Spironolactone—dilated cardiomyopathy	0.000521	0.0102	CcSEcCtD
Vemurafenib—Nausea—Spironolactone—dilated cardiomyopathy	0.000494	0.00967	CcSEcCtD
Vemurafenib—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000471	0.00921	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000469	0.00917	CcSEcCtD
Vemurafenib—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000453	0.00885	CcSEcCtD
Vemurafenib—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000452	0.00884	CcSEcCtD
Vemurafenib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000444	0.00868	CcSEcCtD
Vemurafenib—Skin disorder—Furosemide—dilated cardiomyopathy	0.00044	0.0086	CcSEcCtD
Vemurafenib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000434	0.00848	CcSEcCtD
Vemurafenib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000431	0.00843	CcSEcCtD
Vemurafenib—Chills—Lisinopril—dilated cardiomyopathy	0.000429	0.00839	CcSEcCtD
Vemurafenib—Hypotension—Furosemide—dilated cardiomyopathy	0.000423	0.00827	CcSEcCtD
Vemurafenib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000423	0.00826	CcSEcCtD
Vemurafenib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000416	0.00814	CcSEcCtD
Vemurafenib—Erythema—Lisinopril—dilated cardiomyopathy	0.000416	0.00814	CcSEcCtD
Vemurafenib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000408	0.00797	CcSEcCtD
Vemurafenib—Back pain—Lisinopril—dilated cardiomyopathy	0.000403	0.00787	CcSEcCtD
Vemurafenib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000394	0.0077	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000391	0.00764	CcSEcCtD
Vemurafenib—Fatigue—Furosemide—dilated cardiomyopathy	0.00039	0.00763	CcSEcCtD
Vemurafenib—Constipation—Furosemide—dilated cardiomyopathy	0.000387	0.00757	CcSEcCtD
Vemurafenib—Cough—Lisinopril—dilated cardiomyopathy	0.000363	0.0071	CcSEcCtD
Vemurafenib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000358	0.007	CcSEcCtD
Vemurafenib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000354	0.00693	CcSEcCtD
Vemurafenib—Myalgia—Lisinopril—dilated cardiomyopathy	0.000354	0.00693	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000352	0.00688	CcSEcCtD
Vemurafenib—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00034	0.00664	CcSEcCtD
Vemurafenib—Infection—Lisinopril—dilated cardiomyopathy	0.000337	0.0066	CcSEcCtD
Vemurafenib—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000334	0.00652	CcSEcCtD
Vemurafenib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00033	0.00645	CcSEcCtD
Vemurafenib—Asthenia—Furosemide—dilated cardiomyopathy	0.000325	0.00635	CcSEcCtD
Vemurafenib—Pruritus—Furosemide—dilated cardiomyopathy	0.00032	0.00626	CcSEcCtD
Vemurafenib—Hypotension—Lisinopril—dilated cardiomyopathy	0.000317	0.00621	CcSEcCtD
Vemurafenib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00031	0.00606	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000309	0.00605	CcSEcCtD
Vemurafenib—Dizziness—Furosemide—dilated cardiomyopathy	0.000299	0.00585	CcSEcCtD
Vemurafenib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000295	0.00577	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000293	0.00574	CcSEcCtD
Vemurafenib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000293	0.00573	CcSEcCtD
Vemurafenib—Constipation—Lisinopril—dilated cardiomyopathy	0.00029	0.00568	CcSEcCtD
Vemurafenib—Vomiting—Furosemide—dilated cardiomyopathy	0.000288	0.00563	CcSEcCtD
Vemurafenib—Rash—Furosemide—dilated cardiomyopathy	0.000285	0.00558	CcSEcCtD
Vemurafenib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000285	0.00558	CcSEcCtD
Vemurafenib—Headache—Furosemide—dilated cardiomyopathy	0.000284	0.00555	CcSEcCtD
Vemurafenib—Nausea—Furosemide—dilated cardiomyopathy	0.000269	0.00526	CcSEcCtD
Vemurafenib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000269	0.00525	CcSEcCtD
Vemurafenib—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00025	0.00489	CcSEcCtD
Vemurafenib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000244	0.00477	CcSEcCtD
Vemurafenib—Pruritus—Lisinopril—dilated cardiomyopathy	0.00024	0.0047	CcSEcCtD
Vemurafenib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000232	0.00455	CcSEcCtD
Vemurafenib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000225	0.00439	CcSEcCtD
Vemurafenib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000216	0.00422	CcSEcCtD
Vemurafenib—Rash—Lisinopril—dilated cardiomyopathy	0.000214	0.00419	CcSEcCtD
Vemurafenib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000214	0.00418	CcSEcCtD
Vemurafenib—Headache—Lisinopril—dilated cardiomyopathy	0.000213	0.00416	CcSEcCtD
Vemurafenib—Nausea—Lisinopril—dilated cardiomyopathy	0.000202	0.00395	CcSEcCtD
Vemurafenib—RAF1—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000141	0.00173	CbGpPWpGaD
Vemurafenib—ALB—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00014	0.00171	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—GPX1—dilated cardiomyopathy	0.00014	0.00171	CbGpPWpGaD
Vemurafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000138	0.00168	CbGpPWpGaD
Vemurafenib—BRAF—PDGFR-beta signaling pathway—RAF1—dilated cardiomyopathy	0.000137	0.00167	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—RAC1—dilated cardiomyopathy	0.000137	0.00167	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ACTN2—dilated cardiomyopathy	0.000136	0.00166	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000136	0.00166	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000135	0.00165	CbGpPWpGaD
Vemurafenib—RAF1—Ceramide signaling pathway—TNF—dilated cardiomyopathy	0.000133	0.00163	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—PSEN2—dilated cardiomyopathy	0.000133	0.00162	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000132	0.00162	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000132	0.00162	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways in Glioblastoma—EGFR—dilated cardiomyopathy	0.000132	0.00161	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000131	0.0016	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000131	0.0016	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.00013	0.00159	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	0.00013	0.00159	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.000129	0.00157	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000128	0.00156	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—ITGB1—dilated cardiomyopathy	0.000127	0.00155	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000127	0.00155	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000126	0.00154	CbGpPWpGaD
Vemurafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000125	0.00153	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—RAC1—dilated cardiomyopathy	0.000124	0.00152	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000123	0.0015	CbGpPWpGaD
Vemurafenib—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000122	0.00149	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000122	0.00149	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.000121	0.00148	CbGpPWpGaD
Vemurafenib—RAF1—SHP2 signaling—EGFR—dilated cardiomyopathy	0.00012	0.00147	CbGpPWpGaD
Vemurafenib—RAF1—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.00012	0.00146	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—FASLG—dilated cardiomyopathy	0.000119	0.00146	CbGpPWpGaD
Vemurafenib—BRAF—Regulation of Actin Cytoskeleton—RAF1—dilated cardiomyopathy	0.000119	0.00145	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000119	0.00145	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—RAC1—dilated cardiomyopathy	0.000117	0.00143	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—CD36—dilated cardiomyopathy	0.000117	0.00143	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000116	0.00142	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.000116	0.00142	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VCL—dilated cardiomyopathy	0.000116	0.00141	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000115	0.00141	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000115	0.00141	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	0.000115	0.00141	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—RAC1—dilated cardiomyopathy	0.000115	0.00141	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.000113	0.00138	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000111	0.00136	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.000111	0.00136	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—CD36—dilated cardiomyopathy	0.000111	0.00136	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000111	0.00136	CbGpPWpGaD
Vemurafenib—RAF1—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	0.000108	0.00132	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000108	0.00132	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000108	0.00132	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	0.000108	0.00132	CbGpPWpGaD
Vemurafenib—BRAF—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.000108	0.00132	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000108	0.00132	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000108	0.00132	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000107	0.00131	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—RAC1—dilated cardiomyopathy	0.000107	0.0013	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000104	0.00127	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.000104	0.00127	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—dilated cardiomyopathy	0.000103	0.00126	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—RAC1—dilated cardiomyopathy	0.000102	0.00125	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000102	0.00124	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000102	0.00124	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—RAF1—dilated cardiomyopathy	9.81e-05	0.0012	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	9.63e-05	0.00118	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—PSEN2—dilated cardiomyopathy	9.48e-05	0.00116	CbGpPWpGaD
Vemurafenib—BRAF—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	9.42e-05	0.00115	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	9.2e-05	0.00112	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways in Glioblastoma—EGFR—dilated cardiomyopathy	9.12e-05	0.00111	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	9.07e-05	0.00111	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ANKRD1—dilated cardiomyopathy	8.86e-05	0.00108	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	8.86e-05	0.00108	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	8.52e-05	0.00104	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TTN—dilated cardiomyopathy	8.46e-05	0.00103	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—TAZ—dilated cardiomyopathy	8.33e-05	0.00102	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—ITGB1—dilated cardiomyopathy	8.31e-05	0.00101	CbGpPWpGaD
Vemurafenib—BRAF—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	8.17e-05	0.000998	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	8.09e-05	0.000987	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	7.95e-05	0.00097	CbGpPWpGaD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—TNF—dilated cardiomyopathy	7.92e-05	0.000967	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	7.8e-05	0.000952	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—EGFR—dilated cardiomyopathy	7.64e-05	0.000933	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	7.64e-05	0.000933	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	7.56e-05	0.000923	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—SDHA—dilated cardiomyopathy	7.54e-05	0.00092	CbGpPWpGaD
Vemurafenib—RAF1—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	7.48e-05	0.000913	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	7.42e-05	0.000906	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—RAC1—dilated cardiomyopathy	7.38e-05	0.000901	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ACTN2—dilated cardiomyopathy	7.33e-05	0.000895	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	7.33e-05	0.000895	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	7.32e-05	0.000894	CbGpPWpGaD
Vemurafenib—BRAF—Neuronal System—RAF1—dilated cardiomyopathy	7.21e-05	0.000881	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	7.12e-05	0.00087	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	7.12e-05	0.00087	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	7.12e-05	0.000869	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	7.11e-05	0.000868	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—RAF1—dilated cardiomyopathy	7.07e-05	0.000864	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	7.07e-05	0.000863	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	6.83e-05	0.000834	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—EGFR—dilated cardiomyopathy	6.73e-05	0.000821	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NPPA—dilated cardiomyopathy	6.72e-05	0.00082	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—RAC1—dilated cardiomyopathy	6.68e-05	0.000815	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	6.63e-05	0.00081	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	6.62e-05	0.000808	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PSEN2—dilated cardiomyopathy	6.51e-05	0.000794	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	6.31e-05	0.00077	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VCL—dilated cardiomyopathy	6.24e-05	0.000761	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—ITGB1—dilated cardiomyopathy	5.93e-05	0.000724	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	5.91e-05	0.000721	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ITGB1—dilated cardiomyopathy	5.82e-05	0.00071	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	5.65e-05	0.00069	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	5.65e-05	0.00069	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—EGFR—dilated cardiomyopathy	5.56e-05	0.000679	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	5.56e-05	0.000679	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	5.45e-05	0.000665	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	5.45e-05	0.000665	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—EGFR—dilated cardiomyopathy	5.31e-05	0.000649	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—EGFR—dilated cardiomyopathy	5.29e-05	0.000646	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	5.29e-05	0.000646	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—EGFR—dilated cardiomyopathy	5.26e-05	0.000642	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—EGFR—dilated cardiomyopathy	5.24e-05	0.000639	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	5.19e-05	0.000634	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	5.19e-05	0.000634	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	5.18e-05	0.000633	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	5.14e-05	0.000627	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CD36—dilated cardiomyopathy	5.06e-05	0.000618	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ITGB1—dilated cardiomyopathy	5.03e-05	0.000614	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—CD36—dilated cardiomyopathy	4.96e-05	0.000606	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	4.93e-05	0.000601	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—EGFR—dilated cardiomyopathy	4.93e-05	0.000601	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	4.93e-05	0.000601	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	4.89e-05	0.000597	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—EGFR—dilated cardiomyopathy	4.88e-05	0.000596	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	4.88e-05	0.000596	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—EGFR—dilated cardiomyopathy	4.85e-05	0.000592	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	4.84e-05	0.000591	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—EGFR—dilated cardiomyopathy	4.82e-05	0.000588	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	4.81e-05	0.000588	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—RAC1—dilated cardiomyopathy	4.77e-05	0.000582	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.74e-05	0.000578	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.74e-05	0.000578	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—RAC1—dilated cardiomyopathy	4.68e-05	0.000571	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—EGFR—dilated cardiomyopathy	4.65e-05	0.000568	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NPPA—dilated cardiomyopathy	4.65e-05	0.000567	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	4.64e-05	0.000566	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NPPA—dilated cardiomyopathy	4.61e-05	0.000563	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.6e-05	0.000561	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.56e-05	0.000556	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—TAZ—dilated cardiomyopathy	4.53e-05	0.000553	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PSEN2—dilated cardiomyopathy	4.5e-05	0.00055	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.48e-05	0.000547	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD36—dilated cardiomyopathy	4.47e-05	0.000545	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PSEN2—dilated cardiomyopathy	4.46e-05	0.000545	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	4.42e-05	0.000539	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.41e-05	0.000539	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	4.4e-05	0.000538	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	4.36e-05	0.000533	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD36—dilated cardiomyopathy	4.29e-05	0.000524	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	4.27e-05	0.000521	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	4.22e-05	0.000515	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—RAC1—dilated cardiomyopathy	4.21e-05	0.000514	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SDHA—dilated cardiomyopathy	4.09e-05	0.0005	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.05e-05	0.000494	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.05e-05	0.000494	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—RAC1—dilated cardiomyopathy	4.04e-05	0.000494	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.03e-05	0.000492	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	3.97e-05	0.000485	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.76e-05	0.000459	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	3.74e-05	0.000456	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.64e-05	0.000445	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.64e-05	0.000445	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	3.46e-05	0.000422	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	3.38e-05	0.000413	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	3.37e-05	0.000411	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—dilated cardiomyopathy	3.36e-05	0.00041	CbGpPWpGaD
Vemurafenib—BRAF—Disease—RAC1—dilated cardiomyopathy	3.27e-05	0.000399	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	3.24e-05	0.000395	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	3.17e-05	0.000386	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PSEN2—dilated cardiomyopathy	3.15e-05	0.000385	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	3.13e-05	0.000382	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.11e-05	0.00038	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ITGB1—dilated cardiomyopathy	3.05e-05	0.000372	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—dilated cardiomyopathy	3.04e-05	0.000371	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.95e-05	0.00036	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	2.86e-05	0.000349	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.8e-05	0.000342	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.8e-05	0.000342	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.68e-05	0.000328	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—CD36—dilated cardiomyopathy	2.67e-05	0.000326	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.66e-05	0.000325	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.6e-05	0.000318	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD36—dilated cardiomyopathy	2.6e-05	0.000318	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.6e-05	0.000317	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AGT—dilated cardiomyopathy	2.56e-05	0.000313	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.54e-05	0.00031	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.52e-05	0.000308	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—RAC1—dilated cardiomyopathy	2.52e-05	0.000307	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.5e-05	0.000305	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—RAC1—dilated cardiomyopathy	2.45e-05	0.000299	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	2.44e-05	0.000298	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.43e-05	0.000297	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.34e-05	0.000286	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RAC1—dilated cardiomyopathy	2.29e-05	0.00028	CbGpPWpGaD
Vemurafenib—RAF1—Disease—RAC1—dilated cardiomyopathy	2.26e-05	0.000276	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—RAC1—dilated cardiomyopathy	2.24e-05	0.000274	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	2.21e-05	0.00027	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AGT—dilated cardiomyopathy	2.19e-05	0.000267	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.19e-05	0.000267	CbGpPWpGaD
Vemurafenib—BRAF—Disease—RAF1—dilated cardiomyopathy	2.17e-05	0.000265	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—dilated cardiomyopathy	2.17e-05	0.000265	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.15e-05	0.000263	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—dilated cardiomyopathy	2.06e-05	0.000252	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GPX1—dilated cardiomyopathy	2.05e-05	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.04e-05	0.000249	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CD36—dilated cardiomyopathy	1.99e-05	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—dilated cardiomyopathy	1.91e-05	0.000234	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.84e-05	0.000224	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	1.8e-05	0.00022	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AGT—dilated cardiomyopathy	1.8e-05	0.000219	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	1.75e-05	0.000214	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.75e-05	0.000214	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.75e-05	0.000213	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.7e-05	0.000208	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—RAF1—dilated cardiomyopathy	1.67e-05	0.000204	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.59e-05	0.000194	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	1.58e-05	0.000193	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.53e-05	0.000187	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RAF1—dilated cardiomyopathy	1.52e-05	0.000185	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AGT—dilated cardiomyopathy	1.51e-05	0.000185	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—RAF1—dilated cardiomyopathy	1.49e-05	0.000182	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—dilated cardiomyopathy	1.49e-05	0.000182	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.44e-05	0.000176	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.22e-05	0.000149	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—dilated cardiomyopathy	1.11e-05	0.000136	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPX1—dilated cardiomyopathy	1.11e-05	0.000136	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CD36—dilated cardiomyopathy	1.08e-05	0.000132	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—dilated cardiomyopathy	1.04e-05	0.000127	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—dilated cardiomyopathy	1.03e-05	0.000126	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—dilated cardiomyopathy	1.02e-05	0.000125	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AGT—dilated cardiomyopathy	9.75e-06	0.000119	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	9.18e-06	0.000112	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	8.94e-06	0.000109	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	8.05e-06	9.83e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	7.78e-06	9.49e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	7.57e-06	9.25e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—dilated cardiomyopathy	7.21e-06	8.8e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	6.82e-06	8.33e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	6e-06	7.33e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	5.84e-06	7.14e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	5.26e-06	6.43e-05	CbGpPWpGaD
